查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010009

血庫市場：2026-2032年全球市場預測（按產品類型、檢測類型、採集方法、捐血類型、應用和最終用戶分類）

Blood Banking Market by Product Type, Testing Type, Collection Method, Donor Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血庫市場價值將達到 191.5 億美元，到 2026 年將成長到 214 億美元，到 2032 年將達到 463.1 億美元，複合年成長率為 13.44%。

主要市場統計數據
基準年 2025 191.5億美元
預計年份：2026年 214億美元
預測年份 2032 463.1億美元
複合年成長率 (%) 13.44%

本文介紹了血庫產業的現狀，其中臨床需求、捐贈者多樣化、檢測技術的進步和營運韌性相互交織，重新定義了患者照護的提供方式。

血液銀行業正處於一個關鍵的十字路口，臨床需求、快速的技術進步和不斷變化的供應鏈現實在此交匯。捐血者篩檢、自動化採血和分子檢測技術的進步正在改變血液成分的取得、處理和配對方式，而人口結構和流行病學壓力也在重塑需求模式。臨床相關人員和營運管理人員越來越關注整個採血網路的韌性、檢測的可靠性以及在不中斷臨床服務的前提下實施新的安全措施的能力。

技術進步、臨床實踐的改變、更嚴格的監管以及供應鏈的韌性如何重塑整個血庫系統的營運重點。

在技​​術創新、臨床實踐不斷發展以及確保供應鏈韌性的驅動下，血庫產業正經歷著一場變革。新型病原體去除系統和先進的核酸檢測技術提高了安全標準，並能更有效地降低輸血相關風險。同時，血液成分分離和全血處理的自動化提高了處理能力，減少了人為操作的差異，並能夠製備更高品質的血液成分產品。除了這些技術變革之外，用於招募和留住自願捐血的數位互動平台也在不斷發展，這不僅改善了捐血的體驗，還有助於最佳化採血計畫和改進庫存預測。

本研究評估了關稅波動和貿易政策趨勢如何增加血庫營運採購流程的複雜性，並促使策略供應鏈進行調整。

關稅調整和貿易政策趨勢正對血庫設備、耗材和診斷試劑的採購環境產生重大影響。關鍵生產投入品和成品醫療設備進口關稅的提高可能會增加用於檢測、處理和血液收集的設備和一次性用品的到貨成本。這一趨勢促使採購團隊重新評估其供應商組合，盡可能優先選擇本地或區域製造，並尋求合約保障措施以應對短期成本波動。在臨床計畫中，一個實際後果是，在選擇檢測平台和擴展血液分離能力時，需要更加關注成本的可預測性。

詳細的細分分析揭示了產品類型、檢測方法、血液收集方法、捐贈者類別、應用和最終用戶環境如何需要差異化的運作和臨床策略。

精準理解產品細分對於最佳化臨床路徑、採購策略和營運模式至關重要。依產品類型分析可發現，每種成分（例如冷沉澱、血漿、血小板、紅血球和全血）在物流和臨床需求方面存在差異。每種成分都需要獨特的採集、儲存和檢測流程，這會影響其保存期限和分銷策略。基於用途（診斷、檢查和輸血）的區分決定了所需的檢測深度，並影響可追溯性和文件記錄的優先順序。特別是檢查應用程式可能需要額外的檢體處理和資料管理。

美洲、歐洲、中東和非洲以及亞太地區的區域差異如何造就獨特的營運重點、監管應對措施和供應鏈彈性策略。

區域趨勢對血庫的優先事項和能力起著至關重要的作用。在美洲，成熟的血庫網路和一體化的醫院系統創造了良好的環境，使得整合、先進檢測技術的應用和集中庫存管理得以廣泛實施。該地區對臨床標準化和捐血招募宣傳活動的重視，也促進了血液成分利用實踐和品質系統的持續改進。

本檢驗了製造商、診斷公司和服務供應商如何投資於自動化、夥伴關係和安全創新，以重新定義其競爭地位和臨床價值。

關鍵產業相關人員是創新、策略夥伴關係和產能擴張的核心，他們的活動涵蓋儀器供應商、診斷試劑製造商、實驗室和血漿分餾。領先的製造商持續投資於儀器間的自動化和互通性，以減少人工操作並提高可追溯性；同時，診斷試劑製造商正在加速開發多重檢測和快速血型鑑定解決方案，以支援更快速的臨床決策。儀器製造商與實驗室之間的合作也在不斷拓展，從而促進了硬體、試劑和驗證支援等一體化服務的提供。

為臨床領導、採購團隊和技術合作夥伴提供實用建議，以提高血庫系統的安全性、供應彈性和營運效率。

臨床服務、採購和製造領域的領導者應優先考慮一系列協作舉措，將新的見解與營運韌性和臨床品質聯繫起來。首先，應實現供應商關係多元化，並對關鍵耗材和設備的合格替代供應商檢驗，以減少對單一供應商的依賴，並降低關稅造成的成本波動風險。此外，還應實施合約策略，包括價格調整條款和庫存寄售模式，以平衡成本控制和供應穩定性。

本文描述了一種多方面的調查方法，該方法結合了相關人員訪談、技術檢驗和交叉檢驗的二手資訊。這確保了研究結果的可靠性和可操作性。

本分析基於系統性的研究途徑，該方法結合了與行業相關人員進行的定性研究和嚴謹的第二手資料基準。主要研究包括對血庫營運經理、臨床實驗室主任、採購主管和醫療技術供應商進行半結構式訪談，以收集關於技術應用、捐血者策略和供應鏈限制的第一手觀點。這些研究結果與監管指南、血液採集和檢測平台的技術規範、經同行評審的輸血安全臨床文獻以及公開的企業資訊披露等第二手資料進行交叉比對，以檢驗趨勢並調和不同的觀點。

結論強調韌性、技術採納和跨部門協作是維持臨床安全和業務連續性的支柱。

現代血庫環境既充滿挑戰也蘊藏機遇，需要採取複雜而有策略的因應措施。檢測和處理技術的進步拓展了臨床醫生和操作人員可用的工具，而捐血的多樣性和地理差異則要求採取靈活且因地制宜的方法。貿易政策的變化和供應鏈的中斷進一步增加了營運的複雜性，必須透過來源多元化和製定積極的緊急時應對計畫來主動應對。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血庫市場：依產品類型分類

  • 冷凍機配方
  • 電漿
  • 血小板
  • 紅血球
  • 全血

第9章 依檢測類型分類的血庫市場

  • 血型檢測
  • 傳染病檢查

第10章 依採集方式分類的血庫市場

  • 血液分離術
  • 全血採集

第11章 依捐血者類型分類的血庫市場

  • 家庭代孕捐贈者
  • 付費捐贈者
  • 免費捐贈者

第12章 血庫市場：依應用領域分類

  • 診斷
  • 研究
  • 輸血

第13章 血庫市場：依最終用戶分類

  • 門診手術中心
  • 血庫
  • 醫院和診所

第14章 血庫市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 血庫市場：依群體分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 血庫市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國血庫市場

第18章：中國血庫市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Baxter International Inc.
  • Beckman Coulter, Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Cardinal Health, Inc.
  • Cerus Corporation
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Grifols SA
  • Haemonetics Corporation
  • ICU Medical, Inc.
  • Immucor, Inc.
  • Macopharma SA
  • Nipro Corporation
  • QuidelOrtho Corporation
  • Sarstedt AG & Co. KG
  • Siemens Healthineers AG
  • Terumo BCT, Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04D00

The Blood Banking Market was valued at USD 19.15 billion in 2025 and is projected to grow to USD 21.40 billion in 2026, with a CAGR of 13.44%, reaching USD 46.31 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 19.15 billion
Estimated Year [2026] USD 21.40 billion
Forecast Year [2032] USD 46.31 billion
CAGR (%) 13.44%

Introducing the contemporary blood banking landscape where clinical demands, donor diversity, testing advances, and operational resilience converge to redefine patient care delivery

The blood banking field stands at a pivotal confluence of clinical necessity, technological acceleration, and shifting supply chain realities. Advances in donor screening, automated collection, and molecular testing have altered how blood components are sourced, processed, and matched to recipients, while demographic and epidemiological pressures are reshaping demand patterns. Clinical stakeholders and operations leaders are increasingly focused on resilience across collection networks, testing reliability, and the ability to integrate new safety modalities without disrupting clinical delivery.

Across clinical settings, from ambulatory surgical centers to large hospital systems, the imperative to minimize transfusion risks while maintaining adequate inventories has intensified. This dynamic has stimulated investment in pathogen reduction technologies, automated apheresis systems, and enhanced infectious disease testing platforms. At the same time, the donor landscape is diversifying: family replacement donors, paid donors, and voluntary donors present different operational considerations for recruitment, retention, and regulatory compliance. The interplay between donor type and collection method-whether whole blood collection or apheresis collection-shapes processing workflows and downstream testing priorities.

In the coming years, organizations that align clinical practice with robust donor engagement, reliable testing protocols, and adaptive supply strategies will be best positioned to deliver safe transfusion services. This introduction frames the ensuing analysis by connecting clinical priorities with operational levers, setting the context for deeper consideration of technological, regulatory, and geopolitical shifts that follow.

How technological advancement, clinical practice changes, regulatory tightening, and supply chain resilience are collectively reshaping operational priorities across blood banking systems

The blood banking landscape is undergoing transformative shifts driven by technological innovation, clinical practice evolution, and the imperative of supply chain resilience. Novel pathogen reduction systems and advanced nucleic acid testing have raised the safety baseline, enabling blood services to mitigate transfusion-transmitted risks more effectively. Simultaneously, automation in apheresis and whole blood processing streamlines throughput, reduces manual variability, and supports higher-quality component preparation. These technological shifts are complemented by the increasing adoption of digital engagement platforms to recruit and retain voluntary donors, improving donor experience while optimizing collection scheduling and inventory forecasting.

Clinical change is equally significant. Patient blood management programs and precision transfusion strategies prioritize minimizing unnecessary transfusions and matching specific component types-such as platelets, red blood cells, plasma, and cryoprecipitate-to individual patient needs. As a result, diagnostic testing and rapid blood grouping are taking on heightened importance to support tailored transfusion decisions. Alongside these clinical trends, regulatory frameworks continue to evolve, emphasizing enhanced surveillance for infectious agents and stricter validation of testing methodologies. This regulatory tightening incentivizes investments in validated testing technologies and quality management systems.

Operationally, the sector is responding to the lessons of prior supply disruptions by diversifying supplier relationships, investing in cold-chain logistics, and exploring local manufacturing and processing options. Cross-sector collaborations between blood banks, hospitals and clinics, and diagnostic manufacturers are becoming more common, driven by the need for integrated solutions that deliver on throughput, safety, and traceability. Taken together, these shifts are recalibrating how blood services prioritize capital allocation, workforce development, and strategic partnerships to meet rising expectations from clinicians and patients alike.

Evaluating how tariff shifts and trade policy dynamics are intensifying procurement complexity and prompting strategic supply chain adaptation across blood banking operations

Tariff adjustments and trade policy developments have a material influence on the procurement landscape for blood banking equipment, consumables, and diagnostic reagents. Increases in import duties on key manufacturing inputs and finished medical devices can raise landed costs for instrumentation and disposables used in testing, processing, and collection. This dynamic prompts procurement teams to reassess supplier portfolios, prioritize local or regional manufacturing where feasible, and seek contractual protections that absorb short-term cost fluctuations. For clinical programs, the practical consequence is a heightened focus on cost predictability when selecting testing platforms or scaling up apheresis capabilities.

Beyond direct price effects, tariff-related uncertainty can elongate lead times and complicate inventory planning. Manufacturers and distributors may adjust distribution strategies to hedge against tariff volatility, which in turn requires blood banks and hospitals to build more robust inventory buffers or to qualify alternate validated devices and reagent sources. Procurement and clinical engineering functions therefore must collaborate more closely to evaluate equivalency across suppliers and to validate alternate products without compromising clinical performance or regulatory compliance.

Furthermore, tariffs can act as a catalyst for nearshoring and regional supply chain development, incentivizing suppliers to establish manufacturing or assembly operations closer to end markets. While such shifts can enhance long-term resilience, they also require capital investment and time, so organizations should prioritize scenario planning, engage in proactive supplier negotiations, and incorporate total-cost-of-ownership analyses into purchasing decisions. Ultimately, the cumulative effects of tariff dynamics underscore the importance of strategic procurement governance, cross-functional contingency planning, and agile operations to maintain continuity of safe transfusion services.

Deep segmentation analysis reveals how product types, testing modalities, collection methods, donor categories, applications, and end-user settings demand differentiated operational and clinical strategies

A nuanced understanding of segmentation is essential for tailoring clinical pathways, procurement choices, and operational models. When analyzed by product type, differences emerge between the logistical and clinical requirements for components such as cryoprecipitate, plasma, platelets, red blood cells, and whole blood, each demanding specific collection, storage, and testing workflows that affect shelf life and distribution strategies. Application-driven differentiation-spanning diagnostics, research, and transfusion use cases-shapes the depth of testing required and influences priorities around traceability and documentation, especially where research applications may require additional sample processing and data handling.

End-user contexts also prescribe operational distinctions: ambulatory surgical centers, blood banks, and hospitals and clinics each operate under different throughput, staffing, and facility constraints, meaning that solutions must be calibrated to fit institutional scale and clinical intensity. Testing type segmentation, separating blood grouping testing from infectious disease testing, clarifies technology selection and quality control approaches because these testing categories carry distinct regulatory pathways and validation requirements. Collection method considerations-comparing apheresis collection with whole blood collection-highlight trade-offs in donor time commitment, component yield, and downstream processing complexity, which have implications for donor engagement strategies and capacity planning.

Donor type segmentation further complicates operational design. Family replacement donors, paid donors, and voluntary donors each present unique ethical, regulatory, and logistical dimensions that impact recruitment practices and community outreach. Taken together, these segmentation lenses enable providers and suppliers to align product portfolios, testing algorithms, and service delivery models with the specific clinical and operational needs of diverse customers and patient populations.

How regional variations across the Americas, Europe Middle East & Africa, and Asia-Pacific produce distinct operational priorities, regulatory responses, and supply resilience strategies

Regional dynamics play a pivotal role in shaping blood banking priorities and capabilities. In the Americas, established networks of blood banks and integrated hospital systems create an environment where consolidation, advanced testing adoption, and centralized inventory management are prevalent. This region's focus on clinical standardization and donor recruitment campaigns supports continued refinement of component utilization practices and quality systems.

Across Europe, Middle East & Africa, heterogeneity in health system maturity drives diverse operational models. High-income markets within the region emphasize rigorous regulatory compliance, molecular testing adoption, and investment in pathogen reduction methodologies, while lower-resource settings prioritize scalable collection strategies, cold-chain logistics, and capacity building. Public-private partnerships and regional initiatives often serve as mechanisms to spread best practices and standardize training, enhancing cross-border collaboration in emergency responses and rare-donor management.

In Asia-Pacific, population dynamics and rapid healthcare modernization are accelerating demand for robust collection and testing infrastructure. The region exhibits a mix of centralized and distributed collection models, with increasing investment in automated apheresis systems and point-of-care blood grouping technologies. Policymakers and providers in this region are also exploring regional manufacturing opportunities to reduce dependence on long international supply lines, thereby strengthening resilience against trade-related disruptions and improving access to critical consumables.

Examining how manufacturers, diagnostics firms, and service providers are investing in automation, partnerships, and safety innovations to realign competitive positioning and clinical value

Key industry participants have become focal points for innovation, strategic partnerships, and capacity expansion, with activity spanning equipment suppliers, diagnostic manufacturers, testing laboratories, and plasma fractionators. Leading manufacturers continue to invest in automation and device interoperability to reduce manual touches and improve traceability, while diagnostic firms are accelerating development of multiplexed assays and rapid blood grouping solutions that enable faster clinical decision making. Collaborative arrangements between equipment makers and testing laboratories are also growing, facilitating integrated service offerings that bundle hardware, reagents, and validation support.

Strategic partnerships and targeted acquisitions are shaping the competitive landscape as companies seek to broaden their clinical portfolios or secure downstream distribution channels. Some organizations are prioritizing investments in pathogen reduction technologies and expanded reagent libraries to meet heightened safety expectations. Meanwhile, suppliers focused on collection technologies are advancing apheresis system ergonomics and throughput, improving donor experience and supporting higher yield per collection event. Across the sector, there is a clear emphasis on building solutions that address both clinical efficacy and operational efficiency, enabling end users such as hospitals and blood banks to more readily adopt new modalities while maintaining compliance with regulatory standards.

Actionable recommendations for clinical leaders, procurement teams, and technology partners to fortify safety, supply resilience, and operational efficiency within blood banking systems

Leaders in clinical services, procurement, and manufacturing should prioritize a set of coordinated actions that translate emerging insights into operational resilience and clinical quality. First, diversify supplier relationships and qualify alternate validated vendors for critical consumables and instruments to reduce single-source exposure and mitigate tariff-driven cost volatility. Complement this with contractual strategies that include price adjustment clauses and inventory consignment models to balance cost management with availability.

Invest in diagnostic and processing technologies that strengthen the safety envelope while improving throughput. Adoption of advanced infectious disease testing platforms and pathogen reduction systems can reduce clinical risk and streamline regulatory compliance, while automation in collection and component processing can cut variability and labor intensity. Parallel to technology investments, enhance donor engagement through digital platforms that simplify scheduling and retention for voluntary donors, and tailor outreach programs to the characteristics of family replacement and paid donor pools when applicable.

Operationally, develop cross-functional contingency plans that integrate clinical engineering, supply chain, and clinical leadership to ensure rapid validation of alternate products and seamless substitution during disruptions. Strengthen cold-chain logistics and inventory governance using data-driven replenishment triggers and scenario-based stock policies. Finally, invest in workforce training and competency programs to ensure clinical staff and laboratory personnel can operate new platforms effectively and maintain quality documentation to meet evolving regulatory expectations.

Description of the multi-method research approach combining stakeholder interviews, technical validation, and cross-checked secondary sources to ensure robust and actionable findings

This analysis is grounded in a structured research approach combining primary qualitative engagement with sector stakeholders and a rigorous secondary evidence baseline. Primary research involved semi-structured interviews with operational leaders in blood banks, clinical laboratory directors, procurement executives, and medical technology suppliers to capture firsthand perspectives on technology adoption, donor strategies, and supply chain constraints. These insights were triangulated with secondary materials, including regulatory guidance, technical specifications for collection and testing platforms, peer-reviewed clinical literature on transfusion safety, and publicly available company disclosures to validate trends and reconcile differing narratives.

Data synthesis prioritized thematic convergence across clinical, operational, and supply chain domains. Where possible, technical specifications and regulatory requirements were cross-checked against manufacturer documentation and published standards to ensure accuracy. Throughout the research process, attention was given to contextual differences across end users and regions, acknowledging the limitations inherent to heterogeneous healthcare settings. Findings were reviewed by subject-matter experts with clinical laboratory and transfusion medicine experience to validate practical applicability and to surface nuanced implications for implementation in real-world operations.

Concluding synthesis that emphasizes resilience, technological adoption, and cross-functional coordination as the pillars for sustained clinical safety and operational continuity

The contemporary blood banking environment presents both challenges and opportunities that require calibrated, strategic responses. Technological advancements in testing and processing are expanding the toolkit available to clinicians and operators, while donor diversity and regional variability demand flexible and context-sensitive approaches. Trade policy changes and supply chain disruptions add a layer of operational complexity that must be actively managed through diversified sourcing and proactive contingency planning.

Organizations that integrate clinical quality imperatives with disciplined procurement governance, invest in technologies that enhance safety and throughput, and cultivate strong partnerships across the supply chain will be better positioned to maintain continuity of care. The path forward emphasizes resilience, data-driven decision making, and adaptive strategies that align clinical objectives with the realities of sourcing and operational capacity. By focusing on these priorities, stakeholders can sustain safe transfusion services and respond more effectively to emergent risks and opportunities.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Banking Market, by Product Type

  • 8.1. Cryoprecipitate
  • 8.2. Plasma
  • 8.3. Platelets
  • 8.4. Red Blood Cells
  • 8.5. Whole Blood

9. Blood Banking Market, by Testing Type

  • 9.1. Blood Grouping Testing
  • 9.2. Infectious Disease Testing

10. Blood Banking Market, by Collection Method

  • 10.1. Apheresis Collection
  • 10.2. Whole Blood Collection

11. Blood Banking Market, by Donor Type

  • 11.1. Family Replacement Donor
  • 11.2. Paid Donor
  • 11.3. Voluntary Donor

12. Blood Banking Market, by Application

  • 12.1. Diagnostics
  • 12.2. Research
  • 12.3. Transfusion

13. Blood Banking Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Blood Banks
  • 13.3. Hospitals And Clinics

14. Blood Banking Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Blood Banking Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Blood Banking Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Blood Banking Market

18. China Blood Banking Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Baxter International Inc.
  • 19.7. Beckman Coulter, Inc.
  • 19.8. Becton Dickinson and Company
  • 19.9. Bio-Rad Laboratories, Inc.
  • 19.10. Cardinal Health, Inc.
  • 19.11. Cerus Corporation
  • 19.12. F. Hoffmann-La Roche Ltd
  • 19.13. Fresenius Kabi AG
  • 19.14. Grifols S.A.
  • 19.15. Haemonetics Corporation
  • 19.16. ICU Medical, Inc.
  • 19.17. Immucor, Inc.
  • 19.18. Macopharma SA
  • 19.19. Nipro Corporation
  • 19.20. QuidelOrtho Corporation
  • 19.21. Sarstedt AG & Co. KG
  • 19.22. Siemens Healthineers AG
  • 19.23. Terumo BCT, Inc.
  • 19.24. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD BANKING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD BANKING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD BANKING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD BANKING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD BANKING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD BANKING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD BANKING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD BANKING MARKET SIZE, BY CRYOPRECIPITATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD BANKING MARKET SIZE, BY CRYOPRECIPITATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD BANKING MARKET SIZE, BY CRYOPRECIPITATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD BANKING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD BANKING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD BANKING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD BANKING MARKET SIZE, BY PLATELETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD BANKING MARKET SIZE, BY PLATELETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD BANKING MARKET SIZE, BY PLATELETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD BANKING MARKET SIZE, BY RED BLOOD CELLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD BANKING MARKET SIZE, BY RED BLOOD CELLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD BANKING MARKET SIZE, BY RED BLOOD CELLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD BANKING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD BANKING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD BANKING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD BANKING MARKET SIZE, BY BLOOD GROUPING TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD BANKING MARKET SIZE, BY BLOOD GROUPING TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD BANKING MARKET SIZE, BY BLOOD GROUPING TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD BANKING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD BANKING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD BANKING MARKET SIZE, BY INFECTIOUS DISEASE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD BANKING MARKET SIZE, BY APHERESIS COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD BANKING MARKET SIZE, BY APHERESIS COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD BANKING MARKET SIZE, BY APHERESIS COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD BANKING MARKET SIZE, BY WHOLE BLOOD COLLECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD BANKING MARKET SIZE, BY WHOLE BLOOD COLLECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD BANKING MARKET SIZE, BY WHOLE BLOOD COLLECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD BANKING MARKET SIZE, BY FAMILY REPLACEMENT DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD BANKING MARKET SIZE, BY FAMILY REPLACEMENT DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD BANKING MARKET SIZE, BY FAMILY REPLACEMENT DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD BANKING MARKET SIZE, BY PAID DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD BANKING MARKET SIZE, BY PAID DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD BANKING MARKET SIZE, BY PAID DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD BANKING MARKET SIZE, BY VOLUNTARY DONOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD BANKING MARKET SIZE, BY VOLUNTARY DONOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD BANKING MARKET SIZE, BY VOLUNTARY DONOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD BANKING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD BANKING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD BANKING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD BANKING MARKET SIZE, BY RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD BANKING MARKET SIZE, BY RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD BANKING MARKET SIZE, BY RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD BANKING MARKET SIZE, BY TRANSFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD BANKING MARKET SIZE, BY TRANSFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD BANKING MARKET SIZE, BY TRANSFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD BANKING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD BANKING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD BANKING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD BANKING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD BANKING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD BANKING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD BANKING MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD BANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS BLOOD BANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA BLOOD BANKING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD BANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. GCC BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GCC BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. GCC BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 131. GCC BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. G7 BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. G7 BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. G7 BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. NATO BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. NATO BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NATO BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. NATO BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA BLOOD BANKING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA BLOOD BANKING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA BLOOD BANKING MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA BLOOD BANKING MARKET SIZE, BY COLLECTION METHOD, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA BLOOD BANKING MARKET SIZE, BY DONOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA BLOOD BANKING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA BLOOD BANKING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)